Cupido aims to hit the core of cardiovascular disease, developing inhalable nanoparticles that can deliver a therapy directly to the diseased heart.
The EU-based consortium, composed of 6 academic research groups, 5 SMEs, 2 industries, and 1 pharmaceutical company, gathered a vast array of expertise and joins cutting-edge research with pre-clinical experience and industrial manufacturing.
The role of Nemera in this consortium was to develop the inhaler that administers the nanoparticles to the diseased heart.
The EU-based consortium, composed of 6 academic research groups, 5 SMEs, 2 industries, and 1 pharmaceutical company, gathers a vast array of expertise and joins cutting-edge research with pre-clinical experience and industrial manufacturing:
- Nemera
- CNR – National Research Council of Italy
- Charité – Universitätsmedizin Berlin
- Simula Research Laboratory AS
- Imperial College of Science, Technology and Medicine
- BET solution
- IN S.r.l
- Cambridge Innovation Technologies Consulting Ltd
- Sanofi-Aventis Recherche & Developpement
- FIN-CERAMICA Faenza S.p.A.
- I.F.E. Corporation S.A.
- PlumeStars S.r.l